



Supplementary Figure 1. Secondary efficacy outcomes over time.



ADA: adalimumab; MTX: methotrexate; CRP: C-reactive protein; TJC: tender joint count; SJC: swollen joint count; PhGA: physician's global assessment; PtGA: patient's global assessment; VAS: visual analog scale.

Supplementary Figure 2. Comparison between patients who had a smaller reduction in MTX and those who experienced a larger reduction in MTX.



ADA: adalimumab; MTX: methotrexate; DAS28(CRP): 28-joint Disease Activity Score by C-reactive protein.